Puberty Blocker Manufacturer Paid Director of Mount Sinai Transgender Clinic for Consulting

Puberty Blocker Manufacturer Paid Director of Mount Sinai Transgender Clinic for Consulting


The director of Mount Sinai’s Transgender Center has received compensation from a pharmaceutical company that manufactures puberty blockers.

Doctor Joshua D. Safer, the Executive Director of the Mount Sinai Center for Transgender Medicine and Surgery, has received compensation from Endo Pharmaceuticals, which produces Supprelin LA, a drug commonly used as an off-label puberty blocker.

The Center accepts children as patients, explaining that their “medicine and pediatric endocrinology specialists provide gender-affirming medical care” for children and adolescents. 

In 2018, the most recent year for which public records data is available, Safer received $3,266 from Endo Pharmaceuticals, including $2,347 for consulting. This consulting was directly linked to Supprelin LA. Mount Sinai’s Adolescent Health Center offers puberty-blocking prescriptions to children.

Trending: Ilhan Omar Voted Out Today?

Safer has been a vocal advocate

Continue reading


 

Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Thanks for sharing!
Send this to a friend